Martín L C, Velasco-Cornejo I F, Franco R J
Faculdade de Medicina de Botucatu, São Paulo.
Arq Bras Cardiol. 1994 May;62(5):369-74.
To evaluate the adverse reactions of fosinopril with other antihypertensives used as monotherapy.
Out-patients (n = 2,568) with diagnostic of mild to moderate hypertension, diastolic blood pressure (DBP) 95-115mmHg, with no antihypertensive treatment for 15 days, were included to treatment initially with fosinopril (F) 10mg, once daily, for six weeks. After this period, patients with DBP > 95mmHg had the dosage, once daily, increased to 20mg, while the others were maintained with the same dosage for six more weeks. Adverse reactions of 822 patients treated as monotherapy were grouped as absent, musculoskeletal, cardiovascular, cough, gastrointestinal, neurological, genital-urinary dysfunctions and dermatological and compared with 1,568 with F. Monotherapy consist in alpha-methyldopa (100 patients); beta-blocker (129); calcium blocker (106); diuretic (394); and another ACE inhibitors (93).
At the end of the period without treatment, the blood pressure (BP), 165 +/- 16/105 +/- 7mmHg decreased significantly at 6th week to 144 +/- 15/91 +/- 9mmHg (p < 0.05 vs week 0) with further lowering to 139 +/- 13/86 +/- 7mmHg till the end of 12th week. BP response (DBP < or = 90mmHg) was obtained in 89% of the patients with F. Absence of adverse reactions were > or = 70% in patients with F compared to other drugs.
Fosinopril has demonstrated therapeutic efficacy and less adverse reactions compared to antihypertensives used previously as monotherapy.
评估福辛普利与其他用作单一疗法的抗高血压药物的不良反应。
纳入2568例门诊患者，诊断为轻度至中度高血压，舒张压（DBP）为95 - 115mmHg，且15天内未接受抗高血压治疗，初始用福辛普利（F）10mg，每日一次，治疗六周。六周后，DBP>95mmHg的患者将剂量增至每日一次20mg，其他患者继续维持原剂量六周。将822例接受单一疗法治疗患者的不良反应分为无、肌肉骨骼、心血管、咳嗽、胃肠道、神经、泌尿生殖系统功能障碍和皮肤不良反应，并与1568例使用F的患者进行比较。单一疗法包括α-甲基多巴（100例患者）；β受体阻滞剂（129例）；钙通道阻滞剂（106例）；利尿剂（394例）；以及其他血管紧张素转换酶抑制剂（93例）。
在未治疗期结束时，血压（BP）为165±16/105±7mmHg，在第6周时显著降至144±15/91±9mmHg（与第0周相比，p<0.05），到第12周结束时进一步降至139±13/86±7mmHg。使用F的患者中89%获得了血压反应（DBP≤90mmHg）。与其他药物相比，使用F的患者中不良反应发生率≥70%。
与先前用作单一疗法的抗高血压药物相比，福辛普利已显示出治疗效果且不良反应较少。
